Press releases

13 May 2022

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

10 May 2022

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

2 May 2022

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

28 Apr 2022

UCB’s General Meeting of Shareholders 2022

22 Apr 2022

Disposal of own shares

15 Apr 2022

Disposal of own shares

Press releases

Press releases

Search Press releases

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

UCB’s General Meeting of Shareholders 2022

Disposal of own shares

Disposal of own shares

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

UCB’s General Meeting of Shareholders 2022

Disposal of own shares

Disposal of own shares

Choose a Country